The last time that board expanded, it was to reward Dr. Malik for bringing Woodford on board. After the blow up with Woodford, the board didn’t expand for many years.
Once again Flip we ask that you please spend 5 minutes of simple research before you start connecting dots. Proper due diligence could possibly prevent a situation like you're in now.
Unbelievable!!
Dr. Malik joined the board in 2012.
Bethesda, Maryland, April 17, 2012 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio), a biotech company developing DCVax® personalized immune therapies for cancer, is pleased to announce the addition of Dr. Navid Malik and Mr. Jerry Jasinowski to the Company’s Board of Directors. These new members bring to the NW Bio Board longstanding, deep experience in the life sciences industry, advanced manufacturing, and corporate operations and governance.
The first mention of a Woodford investment was in 2014.
BETHESDA, MD, November 19, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today two financings totaling $35 million. The financings include a $25 million equity investment by UK based C.F. Woodford Equity Income Fund (“Woodford”), and a $10 million mortgage on the Company’s recently acquired UK facility.
Woodford purchased $25 million of unregistered shares of the Company’s common stock at $5.79 per share, for a total of 4,317,790 shares. The Company agreed to undertake registration of the shares within the next couple of months.
“We are excited to have the UK’s leading biotech investor come on board with NW Bio,” commented Linda Powers, CEO of NW Bio
News 
Market Data 
Discover 
AI
